A Phase 2a, Randomized, Double-Blind Placebo-controlled, Parallel-group Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs ASP 0819 (Primary)
- Indications Fibromyalgia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astellas Pharma
- 16 Mar 2018 Status changed from active, no longer recruiting to completed.
- 26 Dec 2017 Planned End Date changed from 1 Apr 2018 to 1 Feb 2018.
- 26 Dec 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Feb 2018.